AUR-105
/ Dr. Reddy’s
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
December 15, 2022
SURYA-1: First in Human, Dose Escalation, Dose Expansion Study of AUR105
(clinicaltrials.gov)
- P1 | N=40 | Recruiting | Sponsor: Aurigene Discovery Technologies Limited | Not yet recruiting ➔ Recruiting
Enrollment open • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Solid Tumor
November 04, 2022
SURYA-1: First in Human, Dose Escalation, Dose Expansion Study of AUR105
(clinicaltrials.gov)
- P1 | N=40 | Not yet recruiting | Sponsor: Aurigene Discovery Technologies Limited
New P1 trial • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Solid Tumor
1 to 2
Of
2
Go to page
1